The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Theravance Biopharma Inc shares valued at $582,501 were sold by Farnum Rhonda on Dec 03 ’25. At $18.75 per share, Farnum Rhonda sold 31,067 shares. The insider’s holdings dropped to 277,695 shares worth approximately $5.05 million following the completion of this transaction.
Also, RHONDA FARNUM purchased 31,067 shares, netting a total of over 582,500 in proceeds.
Before that, ERAN BROSHY had added 29,501 shares to its account. In a trade valued at $590,020, the Director bought Theravance Biopharma Inc shares for $20.00 each.
As published in their initiating research note from Oppenheimer on December 03, 2025, Theravance Biopharma Inc [TBPH] has been an Outperform and the price target has been revised to $27. Analysts at B. Riley Securities started covering the stock with ‘”a Buy”‘ outlook in a report released in mid September. As of August 06, 2024, Leerink Partners has decreased its “an Outperform” rating to a “Market perform” for TBPH. Earlier on April 12, 2024, BTIG Research initiated its rating. Their recommendation was “a Buy” for TBPH stock.
Analyzing TBPH Stock Performance
On last trading session, Theravance Biopharma Inc [NASDAQ: TBPH] rose 1.51% to $18.18. The stock’s lowest price that day was $17.8, but it reached a high of $18.575 in the same session. During the last five days, there has been a surge of approximately 2.83%. Over the course of the year, Theravance Biopharma Inc shares have jumped approximately 85.51%. Shares of the company reached a 52-week high of $20.33 on 11/28/25 and a 52-week low of $7.90 on 04/07/25.
Support And Resistance Levels for Theravance Biopharma Inc (TBPH)
According to the 24-hour chart, there is a support level at 17.79, which, if violated, would cause prices to drop to 17.40. In the upper region, resistance lies at 18.58. The next price resistance is at 18.99. RSI (Relative Strength Index) is 54.43 on the 14-day chart, showing neutral technical sentiment.
Is Theravance Biopharma Inc subject to short interest?
Stocks of Theravance Biopharma Inc saw a sharp rise in short interest on 2025-11-28 jumping by 0.51 million shares to 5.59 million. Data from Yahoo Finance shows that the short interest on 2025-10-31 was 5.08 million shares. A jump of 9.13% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 9.82 of the overall float, the days-to-cover ratio (short ratio) jumped to 9.82.
Which companies own the most shares of Theravance Biopharma Inc (TBPH)?
In terms of Theravance Biopharma Inc share price expectations, FactSet research, analysts set an average price target of 33.5 in the next 12 months, up nearly 87.05% from the previous closing price of $17.91. Analysts anticipate Theravance Biopharma Inc stock to reach 40 by 2025, with the lowest price target being 27. In spite of this, 3 analysts ranked Theravance Biopharma Inc stock as Buy at the end of 2025.
